Jennison Associates LLC Has $9.32 Million Stock Position in Sanofi (NASDAQ:SNY)

Jennison Associates LLC trimmed its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 16.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 168,103 shares of the company's stock after selling 32,135 shares during the quarter. Jennison Associates LLC's holdings in Sanofi were worth $9,323,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi during the 4th quarter worth about $31,000. Bessemer Group Inc. boosted its stake in shares of Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after acquiring an additional 242 shares during the last quarter. Golden State Wealth Management LLC lifted its position in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the period. UMB Bank n.a. lifted its position in Sanofi by 30.7% during the first quarter. UMB Bank n.a. now owns 1,124 shares of the company's stock worth $62,000 after buying an additional 264 shares during the period. Finally, Wayfinding Financial LLC purchased a new position in Sanofi during the first quarter worth about $63,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Stock Up 1.7%

NASDAQ SNY traded up $0.82 on Tuesday, reaching $48.75. The stock had a trading volume of 1,269,231 shares, compared to its average volume of 2,310,451. The business has a 50 day moving average price of $49.65 and a 200 day moving average price of $52.13. Sanofi has a 1 year low of $45.80 and a 1 year high of $60.12. The company has a market capitalization of $119.56 billion, a price-to-earnings ratio of 17.41, a P/E/G ratio of 1.10 and a beta of 0.48. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 17.15% and a net margin of 14.56%. The firm had revenue of $10.41 billion for the quarter, compared to analyst estimates of $9.79 billion. During the same period last year, the company earned $1.78 EPS. The business's quarterly revenue was down 11.0% compared to the same quarter last year. On average, analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SNY. Morgan Stanley set a $56.00 price objective on Sanofi in a research note on Monday, June 2nd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a report on Monday, April 28th. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.